E2F4 RNAi (H00001874-R01)
E2F4 RNAi
|
This product is fully covered under the Novus guarantee+ Policy.
Click
here for details.
|
|
Distributor Data...
|
|
|
|
E2F4 RNAi Summary: | | | Specificity: | E2F transcription factor 4, p107/p130-binding (E2F4), mRNA |
|---|
| Publications: | Antibody has at least 4 Background References. |
|---|
| | Note: Not all species have been tested for usefulness with this product. Only those species listed have been tested. We cannot make any guarantees about additional reactivities which may or may not occur. |
View Additional E2F4 Products | Unit Size: | 20 nmol (also available: 10 nmol) |
|---|
| Concentration: | Concentration is not relevant for this product. Please see the protocols for proper use of this product. |
|---|
|
Notes: This product is produced by and distributed for Abnova, a company based in Taiwan. Packaging: | Storage: | Aliquot and store at -20 °C or -80 °C. Avoid freeze-thaw cycles. |
|---|
| Limitations: | This product is for research use only and is not approved for use in humans or in clinical diagnosis. Products are guaranteed for 6 months from date of receipt, except for peptides and proteins which are guaranteed for 3 months. |
|---|
Background: Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene. The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo. Chimera RNAi has many advantages over the conventional siRNAs. First, it has been demonstrated to have reliable knock-down for over 10,000 human genes. Because the human genome is composed of an intricate, genetic network, chimera RNAis unique design has successfully obviated the off-target effects including microRNA-based influence. Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected. Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.
|
Images (1) Reviews (0) Related Products (15) Exploring E2F4 Working with E2F4
|
Jump to: Publications, Images, Protocols/Procedures, Ask a Question
|
Working with E2F4
E2F4 RNAi Images (1)
|
|
|
Publications (4)E2F4 RNAi Background References:- siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Naito Y, Saigo K et al. Nucleic Acids Res. 2004 Jul 1;32 (Web Server issue):W124-9.
- Guidelines for the selection of highly effective siRNA sequences for mammalian chick RNA interference. Ui-Tei K, Saigo K et al. Nucleic Acids Res. 2004 Feb 9;32(3):936-48. Print 2004.
more... - dsCheck: highly sensitive off-target search software for double-stred RNA-mediated RNA interference. Naito Y, Morishita S et al. Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W589-91.
- Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Ui-Tei K, Naito Y, Zenno S et al. Nucleic Acids Res. 2008, Feb 11 [Epub ahead of print].
|
|
|
|
Ask a Scientist
Can't find an answer to your question about E2F4? Ask us by using live
chat or by submitting your questions below:
|
Jump to: Lysates, Peptides and Proteins, Primary Antibodies
|
Related ProductsLysates (3)Peptides and ProteinsPrimary Antibodies (10)| Name | Catalog# | Reactivity | Applications | Images | Publications | Reviews | |
|---|
| E2F4 Antibody | NBP1-21374 | Hu, Mu | IHC-P, IP, WB | (2) | | | | | E2F4 Antibody | NBP1-67548 | Hu, Mu, Rt | ELISA, IHC, WB | (2) | | | | | E2F4 Antibody (SPM179) | NB120-17845 | Hu, Rt | IF, IHC-P, WB | (1) | | | | | E2F4 Antibody | NBP1-21373 | Hu | IP | (1) | | | | | E2F4 Antibody (TFE42) | NBP1-54516 | Hu, Mu, Rt | IP, WB | | | | | | ... and 5 more. See All » |
|
|
